All In MedTech

FDA Clearance Tracker · P970004-S141

INTERSTIM THERAPY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 1, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 1, 2012

Approved

Time to decision

56 days

Received Sep 6, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P970004-S141
Device name
INTERSTIM THERAPY
Applicant location
Minneapolis, MN
Received
Sep 6, 2012
Decided
Nov 1, 2012
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol - OSB
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE POST-APPROVAL STUDY PROTOCOL.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.